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ABSTRACT 
Background: Most preventive agents used for transformed migraine (TM) 
have not been studied specifically for the treatment of this syndrome. Open- 
label trials have demonstrated the effectiveness of levetiracetam in the treatment 
of refractory headaches. 
Objective: The aim of this study was to assess the effectiveness and toler- 
ability of levetiracetam in the preventive treatment of refractory TM. 
Methods: This prospective, open-label, pilot study was conducted at The 
New England Center for Headache, Stamford, Connecticut. We included patients 
aged ~18 years with refractory TM according to the criteria proposed by 
Silberstein et al. All participants had failed on at least 1 but not more than 3 pre- 
ventive drugs. Other preventive drugs were allowed if they had been received 
at a stable dose for >30 days. The dosage of the levetiracetam tablets ranged 
from 1000 to 3000 mg/d in 2 divided doses. The treatment phase lasted 3 months. 
The primary end point was headache frequency (expressed as the number of 
headache days per month), and the secondary end point was the frequency of 
moderate or severe headache (d/mo). Other end points were headache score, 
Migraine Disability Assessment (MIDAS) Questionnaire score, and Headache 
Impact Test (HIT-6) score. Statistical analyses were performed in the intent-to- 
treat (ITT) population (patients who received at least 1 dose of study medica- 
tion) using data subjected to the last-observation-carried-forward algorithm. 
We also conducted per-protocol (PP) analyses in patients who completed the 
study. 
Results: The ITT population consisted of 36 patients (26 women, 10 men; 
mean [SD] age, 46.5 [17.4] years). The mean headache frequency at baseline was 
24.9 d/mo, and a significant reduction in headache frequency was obtained at 1, 
2, and 3 months of treatment (19.4, 18.4, and 16.2 d/mo, respectively; all, P< 0.001 
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vs baseline). At baseline, the mean number of moderate or severe headache days 
was 16.8 d/mo compared with 13.2, 11.9, and 9.7 d/mo at 1, 2, and 3 months, 
respectively (P = NS, <0.01, and <0.01, respectively). The mean MIDAS score was 
significantly reduced at 3 months compared with baseline (40.8 vs 62.8 d/mo; 
P = 0.01). The mean HIT-6 score was 59.4 at 3 months versus 63.4 at baseline 
(P < 0.01). In the PP population, the mean (SD) headache frequency was 
reduced from 26.1 (4.1) d/mo at baseline to 14.3 (4.8) d/mo at the end of the 
study (P < 0.001). The mean (SD) headache score was reduced from 51.3 (17.1) 
at baseline to 34.0 (22.0) at 3 months (P < 0.016). 
Conclusion: The results of this study in patients with TM support he role of 
levetiracetam in the preventive treatment of refractory TM. (Curr Ther Res Clin 
Exp. 2005;66:212-221) Copyright © 2005 Excerpta Medica, Inc. 
Key words: levetiracetam, transformed migraine, chronic daily headache, 
preventive treatment, prevention. 
INTRODUCTION 
Transformed migraine (TM) is the most frequent subtype of chronic daily 
headache (CDH) seen in headache clinics. 1-3 Most patients with TM have a his- 
tory of episodic migraine, reporting aprocess of transformation characterized by 
an increase in headache frequency over months to years, with the associated 
symptoms becoming less severe. Patients then develop apattern of daily or near- 
daily headache, the phenomenology of which may resemble that of chronic 
tension-type headache, with a few attacks of full-blown migraine superimposed. 4 
The pharmacologic treatment of TM poses a challenge to the physician. 
Most preventive agents used for TM have not been examined specifically for 
the treatment of this syndrome; they are used empirically based on their effi- 
cacy in the treatment of episodic migraine. 5 
Neuromodulators are frequently used in the preventive treatment of mi- 
graine 5,6 and TM. 6,7 Multiple threads of research over the past 15 years have led 
to the concept hat migraine is generated from a hyperexcitable brain. 8,9 Al- 
though we do not know whether migraine is generated inthe cortex or brainstem, 
one possible scenario includes a cascade of events beginning with either brain- 
stem or cortical activation followed by the other, leading to activation of ascend- 
ing and descending pathways, with initiation of perimeningeal vasodilatation a d 
neurogenic inflammation, and, ultimately, central sensitization, l°,n From a theo- 
retical perspective, the efficacy of neuromodulators in the preventive treatment 
of migraine may correlate with their neuronal stabilization properties. 
Levetiracetam is an anticonvulsant medication with an incompletely un- 
derstood mechanism of action. 12 Its use has been approved in the United 
States and Europe for the treatment of epilepsy. Case series have suggested 
the effectiveness of levetiracetam in the treatment of refractory headache. 13,14 
However, levetiracetam has not been specifically studied in the treatment of 
TM. Therefore, the aim of this study was to prospectively assess the effec- 
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tiveness and tolerability of levetiracetam in the preventive treatment of 
refractory TM. 
PATIENTS AND METHODS 
This prospective, open-label, pilot study was conducted at The New England 
Center for Headache, Stamford, Connecticut. Inclusion and exclusion criteria 
were as follows: (1) age _18 years; (2) a diagnosis of TM with or without medica- 
tion overuse, according to the criteria proposed by Silberstein et a14; (3) previous 
failure on at least 1 but no more than 3 preventive drugs; (4) previous failure with 
no more than 1 antiepileptic drug used in therapeutic migraine doses for an ade- 
quate time period; (5) a stable dose of preventive medication for at least 1 month 
(other preventive drugs were allowed if a stable dose had been used for >30 days); 
and (6) no use of other antiepileptic drugs within the previous 30 days. 
There was a 1-month baseline observation period, and information was col- 
lected prospectively using headache calendars. After the baseline period, leve- 
tiracetam was started at 250 mg hs and increased by 250 mg every 5 days up to 
a dose of 1000 mg hs. After the dose adjustment (second month), the dose could 
be increased further over the next 2 weeks up to a total dosage of 3000 mg/d in 
2 divided doses. The treatment phase lasted 3 months (1 month of adjustment 
and 2 months of stable dosing). 
Headache information was collected using headache calendars. Disability 
was assessed using the Migraine Disability Assessment (MIDAS) Question- 
naire 15 (scale: 0-5 = grade I [minimal or infrequent disability]; 6-10 = grade II 
[mild or infrequent disability]; 11-20 = grade III [moderate disability]; and _ 21 = 
grade IV [severe disability]) and the Headache Impact Test (HIT-6) version 1.116 
(scale: 38-49 = little or no impact on patient's life; 50-55 = some impact; 56-59 = 
substantial impact; 60-78 = very severe impact). 
The primary end point was headache frequency (ie, the number of headache 
days per month), and the secondary end point was the number of days with 
moderate or severe headache (d/mo). Other end points included headache 
score (frequency multiplied by severity assessed on a 4-point scale [0 = no pain 
to 3 = severe pain]), and MIDAS 15 and HIT-616 scores. 
Patients were instructed to return for monthly follow-up. At all visits, pa- 
tients were specifically asked whether they had experienced any unexpected 
symptoms or signs. Adverse events (AEs) were defined as any untoward medical 
occurrences during the study, regardless of causal relationship with the treat- 
ment. These included any occurrence that was new in onset or aggravated in
severity or frequency from the baseline condition. 
Statistical Analysis 
Statistical analyses were performed in the intent-to-treat (ITT) population 
(patients who received at least 1 dose of study medication) using data subject- 
ed to the last-observation-carried-forward algorithm. We also conducted per- 
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protocol analyses in patients who completed the study. To compare data from 
several time points, we used 1-way analysis of variance after normality testing. 
Data were compared with the paired t test, assuming a 5% 2-tailed signifi- 
cance level. Our study was powered at 80% to detect a 30% difference using 
matching comparisons atthe 5% level. 
This study protocol received institutional review board approval prior to 
the initiation of the study. All participants signed an institutional review board- 
approved informed-consent form. 
RESULTS 
The ITT population consisted of 36 patients (26 women, 10 men; mean [SD] age, 
46.5 [17.4] years) (Table I). Twenty patients (55.6%) completed the study; 
8 (22.2%) withdrew because of AEs, 5 (13.9%) withdrew consent, and 3 (8.3%) 
were lost to follow-up (Figure 1). 
Table I. Baseline demographic and clinical characteristics of the 
study population (N = 36). 
Characteristic Value 
Age, mean (SD), y 46.5 (1 7.4) 
Sex, no. (%) 
Female 26 (72.2) 
Male 10 (27.8) 
Race, no. (%)* 
White 25 (69.4) 
Black 7 (19.4) 
Other t 4 (11.2) 
Preventive medication, no. (%) 
None 11 (30.6) 
Propranolol 11 (30.6) 
Amitriptyline 10 (27.8) 
Nortriptyline 9 (25.0) 
Verapamil 3 (8.3) 
Candesartan 3 (8.3) 
Nadolol 2 (5.6) 
Other ~ 5 (13.9) 
*Percentages do not total 100 due to rounding. 
tlncludes Hispanic and not specified. 
~lncludes magnesium, riboflavin, coenzyme Q10, flunarizine, and venlafaxine. 
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Signed the consent form 
(39 patients) 
l 
Received at least 1 dose 
of study medication 
(36 patients) 
1 
Completed the study 
(20 patients) 
Figure 1. Study design. 
IJ 
Withdrew because of adverse effects 
(8 patients) 
Withdrew consent (5 patients) 
Lost to follow-up (3 patients) 
Effectiveness 
Intent.to- Treat Population 
Eleven patients (30.6%) were not using other preventive drugs when enrolled, 
10 (27.8%) were using 1 preventive drug, and 15 (41.7%) were using 2 or 3 pre- 
ventive drugs. 
Among those who completed the titration phase (33 patients [91.7%]), the 
median dose was 1250 mg (range, 750-2000 mg). The final doses were 750 mg in 
1 patient (3.0%), 1000 mg in 11 (33.3%), 1250 mg in 12 (36.4%), 1500 mg in 7 
(21.2%), and 1750 mg and 2000 mg in 1 patient each (3.0%). 
At baseline, the mean headache frequency was 24.9 d/mo. A significant reduc- 
tion in headache frequency was observed at 1 month (19.4 d/mo), 2 months 
(18.4 d/mo), and 3 months (16.2 d/mo) (all, P< 0.001 vs baseline) (Figure 2). The 
mean number of moderate or severe headache days at baseline (16.8 d/mo) was 
statistically similar compared with 1 month (13.2 d/mo). However, frequencies of 
moderate or severe headache were significantly lower at 2 and 3 months (11.9 
and 9.7 d/mo, respectively; both, P < 0.01 vs baseline) (Figure 3). 
The mean MIDAS 15 score was significantly reduced at 3 months compared with 
baseline (40.8 vs 62.8; P = 0.01). The mean HIT-616 score was 59.4 at 3 months 
compared with 63.4 at baseline (P < 0.01). 
Per-Protocol Population 
In regard to participants completing this study (20 patients [55.6%]), we cor- 
related end points at baseline and completion (Table II). Mean (SD) headache 
frequency was reduced from 26.1 (4.1) d/mo at baseline to 14.3 (4.8) d/mo at the 
end of the study (P < 0.001). We also found significant differences in the number 
of moderate or severe headache days per month between baseline and study 
completion (18.0 [8.3] vs 9.7 [7.8] d/mo; P< 0.006), headache score (51.3 [17.1] 
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Figure 2. Frequency of headache before (baseline), during, and after 3 months of 
preventive treatment with levetiracetam in patients with transformed 
migraine (N = 36). *P < 0.001 versus baseline. 
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Frequency of moderate or severe headache before (baseline), during, and 
after 3 months of preventive treatment with levetiracetam in patients with 
transformed migraine (N -- 36). *P < 0.01 versus baseline. 
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Table II. End points as assessed in the per-protocol analysis (n = 20). Data are expressed 
as mean (SD). 
End Point Baseline 3 Months P 
Frequency of headache, d/ too 26.1 (4.1) 14.3 (4.8) <0.001 
Frequency of moderate or 
severe headache, d /mo <0.006 
Headache score* <0.016 
MIDAS Questionnaire is score t 0.01 
HIT-616 score :~ <0.006 
18.0 (8.3) 9.7 (7.8) 
51.3 (17.1) 34.0 (22.0) 
76.7 (32.1) 29.3 (23.0) 
64.8 (5.9) 57.7 (7.9) 
MIDAS = Migraine Disability Assessment; HIT-6 = Headache Impact Test. 
*Calculated as frequency multiplied by severity as assessed on a 4-point scale (0 = no pain to 3 = 
severe). 
tScale: 0-5 = grade I (minimal or infrequent disability); 6-10 = grade II (mild or infrequent disability); 
11-20 = grade Ill (moderate disability); and _>21 = grade IV (severe disability). 
~Scale: 38-49 -- little or no impact on patient's life; 50-55 = some impact; 56-59 = substantial impact; 
60-78 = very severe impact. 
vs 34.0 [22.0]; P< 0.016), MIDAS 15 score (76.7 [32.1] vs 29.3 [23.0]; P-- 0.01), and 
HIT-6 z6 score (64.8 [5.9] vs 57.7 [7.9]; P < 0.006). 
Tolerability 
AEs were reported by 18 patients (50.0%); 8 patients (22.2%) withdrew from 
the study because of poor tolerability (somnolence, 2 patients [5.6%]; lack of 
concentration, 2 [5.6%]; and chest tightness, constipation, anorgasmia, nd ankle 
edema, 1 [2.8%] each). The most common AEs were somnolence and asthenia 
(10 patients [27.8%] each) and anxiety (5 patients [13.9%]). Weight gain (4 patients 
[11.1%]) and depression and emotional instability (2 patients [5.6%] each) also 
occurred. The following AEs were also reported by 1 patient (2.8%) each: anor- 
gasmia, ankle edema, constipation, and chest tightness. 
DISCUSSION 
TM is the most frequently seen headache syndrome at headache centers, z3,17,18 
Previous tudies show that the transformation process in patients with migraine 
is associated with increases in not only frequency but also associated isability. 19 
Based on a literature search (key terms: refractory headache, treatment, and 
transformed migraine; years, 1980-2005), most studies addressing the treatment of 
refractory headaches have focused on CDH overall, 14,2° while few studies have 
addressed the preventive treatment of TM as a distinctive subgroup of CDH. Most 
reports of TM are anecdotal. 21,22 An open-label trial assessing the possible benefits 
of sodium valproate in patients with CDH that was refractory to multiple standard 
treatments found that 50% of patients had some kind of response and 10% discon- 
tinued medication due to AEs. 2° Shuaib et a123 treated 37 patients with refractory 
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migraine or CDH with topiramate in an open-label study. Thirty percent had an 
excellent result and 30% had a good result. Recent studies have assessed the 
prevention of CDH with botulinum toxin type A, 22 zonisamide, 24 tizanidine (in a 
double-blind study), 25 and quetiapine. 25 The reductions in headache frequency 
were 30% at 1 month in patients treated with tizanidine 25and 37% at 3 months in 
patients treated with zonisamide. 24 A retrospective study found a reduction of 
36.5% in headache frequency at 2 months in patients using daily naratriptan. 26 
We found that levetiracetam ay be an effective drug in the prevention of 
TM. For the ITT population, headache frequency decreased 34.9%, the number 
of days with moderate or severe headache pain decreased by 42.2%, and dis- 
ability scores decreased significantly (both, P _< 0.01). In those who completed 
the study, headache frequency was reduced by 45.2%, and the number of mod- 
erate or severe headache days per month was reduced by 46.1%. 
The treatment of refractory headache, including TM, is quite often unsuccess- 
ful. 1,2,5 Although we believe that ITT analyses provide a more balanced statisti- 
cal approach, subanalyses of patients who completed the study can be of inter- 
est. For refractory headache, a drug that provides significant relief to even a 
small fraction of patients is useful. In a recent study, Saper et a127 found that daily 
opioid therapy for refractory headache was useful in just 25% of patients in the 
long term. However, considering the degree of refractoriness of the sample, they 
concluded that this modality of treatment might provide relief to some selected 
patients with TM. We found that levetiracetam was effective overall, and sub- 
analyses of the completers strongly reinforced the results of the ITT analysis. 
We verified a high rate of AEs in our study population. AEs were reported by 
50.0% of patients and led to a withdrawal rate of 22.2%. Most of those who with- 
drew from the study were using preventive medications in addition to levetirac- 
etam, which may have increased their risk for AEs and/or drug-drug interactions. 
For most neuromodulators, polypharmacy is associated with a higher frequency 
of AEs. 28 Therefore, drug-drug interactions may at least partially explain our find- 
ings. Second, several trials have reported that the AE rates are higher in TM com- 
pared with migraine. 13,21,22 Double-blind trials investigating levetiracetam used as 
monotherapy are necessary to fully assess the tolerability of this drug. 
Our results support previous findings. Drake et a113 investigated levetirac- 
etam use in the prevention of refractory headache, including CDH. Treatment 
with concomitant medications was continued. A clinical benefit was noted after 
1 month of treatment. Ten patients (16.1%) discontinued the drug because of 
AEs. A second study investigated the use of levetiracetam in patients with CDH 
whose treatment had previously failed with 2 to 4 medications; 46.7% of the 
patients reported a reduction in headache frequency of at least 50%, and 26.7% 
discontinued treatment with the drug due to AEs. 14 While these studies investi- 
gated levetiracetam in the prevention of any type of refractory headache, we 
included only patients with TM in our study. 
Caution should be used when analyzing our results for several reasons. 
First, although this pilot study was prospective, it was not placebo controlled. 
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Neither the patients nor the health care providers were blinded to treatment. 
Second, we included patients with TM with and without medication overuse; 
patients overusing medication had previously failed detoxification protocols. 
None of the patients discontinued medication overuse during our study. Be- 
cause studies show that preventive medication is often ineffective in patients 
overusing acute care medication, 5,14,17,18,21 we may have underestimated the 
benefits of levetiracetam by including overusers. However, most of our patients 
(73.3%) were not overusing acute care medication. Additionally, some patients 
were using several different preventive medications. Finally, not all of the 
patients received the same dose of levetiracetam, which may have influenced 
some comparisons regarding efficacy and tolerability. 
CONCLUSIONS 
The results of this pilot study in patients with TM suggest that levetiracetam is 
a promising drug for the preventive treatment of TM, although it has neither 
been submitted to nor approved by the US Food and Drug Administration for 
this use. Because TM evolves from episodic migraine, our data suggest hat lev- 
etiracetam ay have a role in the preventive treatment of frequent episodic 
migraine. A necessary future step forward is to conduct a double-blind, placebo- 
controlled study of levetiracetam in the treatment of TM. 
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